CyTOF in the Cancer Immune Monitoring and Analysis Centers (CIMAC) | Holden Maecker, PhD
In 2017, the NCI established four Cancer Immune Monitoring and Analysis Centers (CIMACs), which perform standardized, state-of-the-art immunological assays for selected cancer immunotherapy clinical trials. One such assay is CyTOF® immunophenotyping, for which the four CIMAC centers performed cross-site harmonization.
In this presentation, Maecker describes the results and lessons learned from those harmonization efforts, as well as plans for using the Maxpar® Direct™ Immune Profiling Assay™, a standardized, dry-format, high-parameter immunophenotyping assay for mass cytometry, in future CIMAC studies.
This presentation was recorded during the 2021 Fluidigm Mass Cytometry Summit, Igniting Insight into Human Health: The CyTOF Edge.
ABOUT THE SPEAKER:
Holden Maecker, PhD
Professor of Microbiology and Immunology
Director of the Human Immune Monitoring Center